Sugi Predict

Sugi Predict / Compounds / SCHEMBL1128734

SCHEMBL1128734

SCHEMBL1128734

Cc1nc(-c2ccc(O)cc2)no1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ CA12 O43570 1/20 0.57
▸ CA1 P00915 1/20 0.57
▸ CA2 P00918 1/20 0.57
▸ CA9 Q16790 1/20 0.57
▸ RAB9A P51151 5/20 0.54
▸ NFKB1 P19838 4/20 0.54
▸ NFKB2 Q00653 4/20 0.54
▸ RELA Q04206 4/20 0.54
▸ LMNA P02545 3/20 0.54
▸ TSHR P16473 1/20 0.54
▸ MAOA P21397 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ NPC1 O15118 5/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ PKM P14618 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415301 0.89 L3MBTL1 (0.69) PLK1L3MBTL1CA12CA1CA2
SCHEMBL2967349 0.83 L3MBTL1 (0.62) PLK1L3MBTL1CA12CA1CA2
SCHEMBL27574154 0.81 PLK1 (0.71) PLK1L3MBTL1CA12CA1CA2
SCHEMBL1170085 0.80 NR1H4 (0.59) PLK1L3MBTL1CA12CA1CA2
SCHEMBL2359857 0.80 NR1H4 (0.66) PLK1L3MBTL1CA12CA1CA2
SCHEMBL1353609 0.80 CA12 (0.62) PLK1L3MBTL1CA12CA1CA2
SCHEMBL2304839 0.80 L3MBTL1 (0.58) PLK1L3MBTL1CA12CA1CA2
SCHEMBL753304 0.80 L3MBTL1 (0.58) PLK1L3MBTL1CA12CA1CA2
SCHEMBL13621955 0.80 L3MBTL1 (0.58) PLK1L3MBTL1CA12CA1CA2
SCHEMBL2360966 0.80 L3MBTL1 (0.58) PLK1L3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3626699-B1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2023-07-12 — — EP disclosed
US-20210198220-A1 SSAO INHIBITOR SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) 2021-07-01 — — US disclosed
EP-3626699-A1 SSAO INHIBITOR Shandong Danhong Pharmaceutical Co., Ltd. (CN) 2020-03-25 — — EP disclosed
EP-1905769-B1 HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2017-03-29 — — EP disclosed
EP-2945950-B1 ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2017-03-01 — — EP disclosed
EP-1810969-B1 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES MSD KK (JP) 2013-08-07 — — EP disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 — — EP disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 — — US disclosed
US-20110212939-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-09-01 — — US disclosed
US-7994331-B2 Heterocycle-substituted benzimidazole derivative MSD K.K. (JP) 2011-08-09 — — US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 — — US disclosed
EP-0760811-B1 IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 MODULATORS INST NAT SANTE RECH MED (FR) 2009-11-18 — — EP disclosed
US-20080186443-A1 Liquid Crystal Composition, Retardation Plate, and Elliptic Polarizing Plate FUJIFILM CORPORATION (JP) 2008-08-07 — — US disclosed
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 — — US disclosed
EP-1905769-A1 HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-02 — — EP disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 — — US disclosed
EP-1810969-A1 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-07-25 — — EP disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 — — EP disclosed
US-6248765-B1 ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) 2001-06-19 — — US disclosed
WO-1996029315-A2 IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1996-09-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198220-A1 SSAO INHIBITOR SSB, ASAH2, AOX1 PLK1 2981/4885L3MBTL1 4861/4885CA12 3166/4885
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 PLK1 4552/4885L3MBTL1 4661/4885CA12 4457/4885
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives GCK, GCKR, SLC5A1 PLK1 4682/4885L3MBTL1 2097/4885CA12 4026/4885
US-20110212939-A1 Heterocyclic GPCR Agonists GPR119, GCGR, GPR27 PLK1 4590/4885L3MBTL1 4361/4885CA12 4746/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 PLK1 4721/4885L3MBTL1 2125/4885CA12 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.